Most Read Articles
4 days ago
Nintedanib does not appear to improve survival in heavily pretreated patients with metastatic colorectal cancer (CRC), according to data from the phase III LUME-Colon 1 trial.
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Nanotechnology structured water shows potential for ED treatment

Audrey Abella
11 May 2018

Nanotechnology structured water was similarly effective as tadalafil in improving erectile function, suggesting that it could be a potential treatment option for erectile dysfunction (ED), according to a study presented at EAU held in Copenhagen, Denmark.

“Nanotechnology structured water … is a new type of water that is prepared using different types of energy fields and modulators to produce this nanotechnology structured water that has new and different characteristics from ordinary water,” said the researchers.

A total of 262 men with ED were randomized to receive a daily dose of nanotechnology structured water 20 mL/kg body weight (group A, n=87), tadalafil 5 mg (group B, n=90), or ordinary bottled water 20 mL/kg (group C, n=85) and completed a 3-month evaluation. [EAU 2018, abstract 591]

The degree of ED and treatment success were determined by using the International Index of Erectile Function-Erectile Function (IIEF-EF) domain (questions 1–5, and question 15), Sexual Encounter Profile questions 1 and 2 (SEP1 and SEP2), and Global Assessment questions 1 and 2 (GAQ1 and GAQ2) related to erectile function.

At 3 months, group A participants exhibited significant improvements from baseline in IIEF-EF (from 14.39 to 22.64; p<0.001), SEP1 (from 62 percent to 83 percent; p<0.001), SEP2 (from 35 percent to 77 percent; p<0.001), GAQ1 (85 percent; p<0.001) and GAQ2 (79 percent; p<0.001).

Group B showed similar improvements at 3 months in terms of IIEF-EF (from 13.89 to 27.38; p<0.001), SEP1 (from 60 percent to 89 percent; p<0.001), SEP2 (from 37 percent to 85 percent; p<0.001), GAQ1 (91 percent; p<0.001), and GAQ2 (84 percent; p<0.001).

These findings reflect similar efficacy between nanotechnology structured water and tadalafil, noted the researchers. “Nanotechnology structured water … is a novel way to treat ED patients without the need for expensive medications with no side effects … [and] offers a reasonable and safe way to treat ED,” they said.

The results also support previous evidence reflecting the role of nanotechnology-based vehicles in translational therapy development for diseases such as ED, as it has a unique design for drug delivery and is believed to enhance growth factor effects by providing a platform that offers improved release, penetration, and bioavailability, as well as a localized and sustained method of delivery. [J Sex Med 2017;14:36-43; J Urol 1994;151:54-61; J Sex Med 2004;1:284-1291]

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Nintedanib does not appear to improve survival in heavily pretreated patients with metastatic colorectal cancer (CRC), according to data from the phase III LUME-Colon 1 trial.
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.